The safety and efficacy of palbociclib in the treatment of metastatic breast cancer

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
   PubMed Web of Science ®Google Scholar
• Kiely BE, Soon YY, Tattersall MH, et al. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol. 2011;29(4):456–463.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Breast. 2017;31:244–259.
   PubMed Web of Science ®Google Scholar
• Thomssen C, Augustin D, Ettl J, et al. ABC3 consensus: assessment by a German group of experts. Breast Care (Basel). 2016;11(1):61–70.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Noguchi S, Pritchard KI, et al. Everolimus plus exemestane in postmenopausal patients with ER(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870–884.
   PubMed Web of Science ®Google Scholar
• Alkorta I, Elguero J. A theoretical study of the structure and protonation of Palbociclib (PD 0332991). /Journal Mol Struct. 2014;1056-1057(2014):209–215.
   Web of Science ®Google Scholar
• Prescribing Information IBRANCE, LAB-0723-1.0. New York, NY: Pfizer Labs; 2015 Feb.
   Google Scholar
• Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3(11):1427–1438.
   PubMed Web of Science ®Google Scholar
• Caldon CE, Daly RJ, Sutherland RL, et al. Cell cycle control in breast cancer cells. J Cell Biochem. 2006;97(2):261–274.
   PubMed Web of Science ®Google Scholar
• Kollmann K, Heller G, Schneckenleithner C, et al. A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell. 2013;24(2):167–181.
   PubMed Web of Science ®Google Scholar
• Butt AJ, McNeil CM, Musgrove EA, et al. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer. 2005;12 Suppl 1(Suppl 1):S47–59.
   PubMed Web of Science ®Google Scholar
• Zwijsen RM, Wientjens E, Klompmaker R, et al. CDK-independent activation of estrogen receptor by cyclin D1. Cell. 1997;88(3):405–415.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res. 2012;18(2):568–576.
   PubMed Web of Science ®Google Scholar
• Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11(5):R77.
   PubMed Web of Science ®Google Scholar
• Lee N, Eisele K, Chionis J, et al. Mechanisms of resistance to CDK4/6 inhibition in ER+ breast cancer. Cancer Res. 2016;76:Abstract P3-06-01.
   Google Scholar
• Herrera-Abreu MT, Palafox M, Asghar U, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res. 2016;76(8):2301–2313.
   PubMed Web of Science ®Google Scholar
• Lenihan C, Bouchekioua-Bouzaghou K, Abdulghani R, et al. CDK4/6 inhibitor resistant ER-positive cells remain dependent on estrogen signalling and retain sensitivity to endocrine therapy SABCS. San Antonio, TX. 2016. P3-03-12.
   Google Scholar
• Schwartz GK, LoRusso PM, Dickson MA, et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer. 2011;104(12):1862–1868.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16(1):25–35.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Ettl J, et al. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. Breast Cancer Res. 2016;18(1):67.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936.
   PubMed Web of Science ®Google Scholar
• Rugo H, Dieras V, Gelmon KA, et al. Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naive postmenopaussal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2. Annals Oncol. 27(suppl 6):vi69 (225PD). 2016.
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, Andre F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209–219.
   PubMed Web of Science ®Google Scholar
• Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439.
   PubMed Web of Science ®Google Scholar
• Turner NC, Andre F, Cristofanelli M, et al. Treatment post progression in women with endocrine -resistant ER+/HER2- advanced breast cancer who recieved palbociclib plus fulvestrant in PALOMA-3. Sabcs. 2016;P4-22-06.
   Google Scholar
• Verma S, Bartlett CH, Schnell P, et al. Palbociclib in combination with fulvestrant in women with hormone receptor-positive/her2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, Phase III study (PALOMA-3). Oncologist. 2016;21(10):1165–1175.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Iyer S, Turner N, et al. Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. Ann Oncol. 2016;27(6):1047–1054.
   PubMed Web of Science ®Google Scholar
• Hu W, Sung T, Jessen BA, et al. Mechanistic investigation of bone marrow suppression associated with palbociclib and its differentiation from cytotoxic chemotherapies. Clin Cancer Res. 2016;22(8):2000–2008.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for ER-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738–1748.
   PubMed Web of Science ®Google Scholar